

Paper No. ____
Filed: May 12, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

LUPIN LTD. and LUPIN PHARMACEUTICALS INC.,
Petitioners

v.

SENJU PHARMACEUTICAL CO., LTD.,
Patent Owner

Case IPR2015-01099 (Patent 8,669,290 B2)

**PATENT OWNER'S MOTION FOR OBSERVATION
REGARDING CROSS-EXAMINATION OF
REPLY WITNESSES DR. M. JAYNE LAWRENCE, Ph.D.
AND IVAN T. HOFMANN, CPA/CFF, CLP**

Patent Owner Senju Pharmaceutical Co., Ltd. et al. (“Senju”), submits this Patent Owner’s Motion for Observation Regarding Cross-Examination of Dr. M. Jayne Lawrence and Mr. Ivan T. Hofmann, pursuant to the Scheduling Order, Paper No. 10 (filed October 27, 2015), and the Joint Stipulation Adjusting Due Dates 1, 2 & 4, Paper No. 16 (filed January 6, 2016).

Observation #1 - In Ex. 2342, at 10:21-11:11, Dr. Lawrence acknowledged that it was her prior testimony that she had never been qualified by any court or by the U.S. Patent and Trademark Office as an expert in chemistry. At 11:12-20, Dr. Lawrence testified that she is not an expert in medicinal chemistry, organic chemistry, or antioxidant chemistry. *See also* EX2342, 9:11-14:10, 16:3-23:10 (additional testimony on Dr. Lawrence’s background and qualifications). This testimony is relevant to the statements and conclusions in Dr. Lawrence’s reply declaration, Ex. 1094, ¶¶ 31, 33, 36-37, 48-49, 51-52, 73, n.5, regarding and relying on chemistry, and in Petitioners’ Reply¹ at pp. 1, 6-9. This testimony is relevant to the weight and understanding to be given to Dr. Lawrence’s statements and conclusions in her declaration because it establishes her lack of qualification to testify on the subject matter for which she has offered opinions.

Observation #2 - In Ex. 2342, at 179:20-180:1, when asked whether the

¹ Petitioners’ Reply (“Reply”) is Paper No. 32, filed April 22, 2016.

claimed formulations of the '290, '131, '813, and '606 patents contain metals or metal cations, Dr. Lawrence testified: "They contain sodium cation." *See also* EX2342, 179:11-19 (on how metals and metal cations differ). This testimony is relevant to the statements in Dr. Lawrence's reply declaration, Ex. 1094, ¶ 31, n.5, regarding the alleged teachings in the Merck Index (EX1096) and Remington: The Science and Practice of Pharmacy (1995) (EX1051) that tyloxapol is "oxidized by metals," and the corresponding arguments in the Reply at p. 7. This testimony is relevant because it establishes that the alleged teachings of the Merck Index and Remington are inapplicable to the '290, '131, '813, and '606 patents (the "patents-at-issue") because the claimed formulations contain metal cations, not metals.

Observation #3 - In Ex. 2342, at 180:21-181:8, Dr. Lawrence testified as follows: "Q. . . . The claimed formulations of the '290, '131, '813, and '606 patents are not formulated for nasal administration; correct? A. That's my understanding, yes. Q. The claimed formulations of the '290, '131, '813, and '606 patents are not formulated for pharyngeal administration; correct? A. Yes, I believe that's -- yes, that's correct." *See also* EX2342, 180:2-5 (the patents-at-issue are formulated for ophthalmic administration). This testimony is relevant to the statements regarding the alleged behavior of tyloxapol in liquid preparations for nasal and/or pharyngeal applications in Dr. Lawrence's reply declaration, Ex. 1094, ¶ 31, n.5, and in the Reply at p. 7. This testimony is relevant because it

establishes that the alleged behavior of tyloxapol in liquid preparations for nasal and/or pharyngeal applications is irrelevant to the subject matter of the patents-at-issue because the claimed formulations are formulated for ophthalmic administration, not nasal or pharyngeal administration.

Observation #4 - In Ex. 2342, at 32:17-33:5, Dr. Lawrence agreed that Ogawa (EX1010) “identified the formulations of examples 6, 7, and 8 as not forming red insoluble matters and described them as stable, excellent for a long period of time” and testified that the formulations of Ogawa examples 6, 7, and 8 did “not [have any problems with instability or degradation] under the conditions tested.” *See also* EX2342, 62:22-64:3. At 33:6-34:2, Dr. Lawrence further testified: “Q. In your view, the Ogawa ’225 patent solved bromfenac’s stability problem by showing that, under the conditions of examples 6, 7, and 8, the formulations were stable; correct? . . . THE WITNESS: The patent states under the one condition that the formulations were tested for. That is 60 degrees, say, at four weeks. It calls the formulations excellently stable.” This testimony is relevant to the statements in Dr. Lawrence’s reply declaration, Ex. 1094, ¶¶ 22, 26-27, 31, 37-42, and in the Reply at pp. 1-9. This testimony is relevant to the weight and understanding to be given to Dr. Lawrence’s declaration statements regarding the alleged motivation of a person of ordinary skill in the art (“POSA”) “to substitute tyloxapol for polysorbate 80” in Ogawa’s example 6.

Observation #5 - In Ex. 2342, at 221:2-14, Dr. Lawrence testified that Doi (EX2030) “does not” teach the use of tyloxapol in any formulation. At 222:1-4, when asked if the alkylphenols of the Doi patent all contain an OH group directly attached to the phenyl ring, Dr. Lawrence testified “[t]hat is correct.” And when asked whether she agreed with the prior testimony of Dr. Laskar² that “[t]he OH group [in tyloxapol] is not directly attached [to the phenyl ring],” Dr. Lawrence testified that “I think the average structure looks like that” and that she had not done any testing to confirm that any individual tyloxapol molecules would have a free hydroxyl on the ring. EX2342, 224:18-225:9. This testimony is relevant to the statements in Dr. Lawrence’s reply declaration, Ex. 1094, ¶¶ 32-33, and in the Reply at pp. 6-7. This testimony is relevant to the weight and understanding to be given Dr. Lawrence’s opinion that Doi teaches a “class of compounds to which tyloxapol belongs,” because Doi does not teach the use of tyloxapol and the alkylphenols disclosed by Doi are structurally different from tyloxapol.

Observation #6 - In Ex. 2342, at 181:11-186:17, Dr. Lawrence agreed that the ’956 application (EX1097) and WO ’610 (EX1098) concern “a method and composition for treatment” “of snoring, sleep apnea, or sudden infant death syndrome and for improvement of nasal breathing” “by nasal and/or pharyngeal

²Dr. Laskar is the expert for the Petitioner in separate, but related, IPR proceedings involving the same family of patents.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.